Giuseppe Curigliano, President Elect of ESMO and Member of the Editorial Board at OncoDaily, shared a post on LinkedIn:
“The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care.”
